Home›Carboplatin›Carboplatin + Topotecan

Does Carboplatin Interact with Topotecan?

Carboplatin and Topotecan have a major drug interaction according to U.S. FDA drug labeling data. Combination causes greater myelosuppression than topotecan alone with sequence-dependent interaction. Dose reduction of both agents required, particularly when coadministered on day 1 versus day 5 of topotecan dosing. The mechanism involves myelosuppression; sequence-dependent interaction affecting severity based on administration timing. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.

Severity
Major
Carboplatin Class
Platinum-based Drug
Topotecan Class
Topoisomerase Inhibitor
Management
Close medical supervision required
Data Source
U.S. FDA via OpenFDA

How This Interaction Works

The interaction between Carboplatin and Topotecan occurs because myelosuppression; sequence-dependent interaction affecting severity based on administration timing. Clinically, this means combination causes greater myelosuppression than topotecan alone with sequence-dependent interaction. dose reduction of both agents required, particularly when coadministered on day 1 versus day 5 of topotecan dosing. This is classified as a major interaction, meaning it could cause serious harm if not properly managed. Your healthcare provider may need to adjust dosages, substitute one medication, or increase monitoring frequency.

What To Tell Your Doctor or Pharmacist

If you are taking Carboplatin and your doctor is considering prescribing Topotecan (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Ask how frequently you should be monitored while these are co-prescribed
  • Ask whether any dosage adjustments are needed
  • Never stop or change either medication without first consulting your healthcare provider
💊 Carboplatin(Carboplatin)+💊 Topotecan(Topotecan)

Severity & Interaction Details

⚠️
major
Use with caution — major interaction
Serious risk of clinically significant harm. Generally avoid; if used, monitor closely.
Severity scale
MinorContra
On record
Yes
Drug A class
Platinum-based Drug
Drug B class
Topoisomerase Inhibitor
Source
NLP:topotecan

What this means in plain English

Combination causes greater myelosuppression than topotecan alone with sequence-dependent interaction. Dose reduction of both agents required, particularly when coadministered on day 1 versus day 5 of topotecan dosing.

What the FDA label says

"Myelosuppression; sequence-dependent interaction affecting severity based on administration timing"

📖 Source: NLP:topotecan

Share this result:

WhatsAppText / SMSEmail
Also share on:XFacebook
Add more drugs
Check Carboplatin and Topotecan against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.